CatSci Ltd is delighted to announce the appointment of Dr. Paul Bradley as its new Head of Business Development. Dr. Bradley joins the team with 28 years’ experience in drug discovery and development, covering both scientific and commercial roles. Paul has a proven track record of success in drug discovery helping to deliver 12 NCEs into development and 3 small molecules into Phase 2 clinical trials. He previously held senior positions with Pfizer, Charnwood Molecular and Concept Life Sciences.
Dr. Ross Burn, CEO, commented: “We are thrilled that Paul has chosen to join our team. Both his technical and commercial knowledge are synergistic with our strategy to continue to grow the business by delivering customised chemistry solutions for drug discovery and development.’’
Dr. Simon Tyler, COO, added: ‘’Paul’s recruitment is a milestone in the emergence of CatSci as a premier service provider to innovator pharma, and will further enhance our business performance. Throughout his career, Paul has demonstrated success in both delivering drug development programmes and accelerating commercial growth. His technical expertise and commercial experience will undoubtedly be a great asset as we seek to serve our customers’ chemistry needs from late-stage lead optimisation all the way through to product launch.”
Speaking about his new role, Dr. Bradley said: “It is a fantastic time to be joining CatSci as the company is experiencing an unprecedented demand for its process research and development services. I am also really looking forward to working with what is a very dynamic and talented team of scientists.’’